Alcon is downgraded to a hold from my buy rating in fall 2023, after it has gone up +18% since then and now appears ...

Aurion Biotech Inc.’s public offering has been delayed after the company missed a filing deadline with the SEC, its attorney ...

Needham analyst David Saxon lowered the firm’s price target on Alcon (ALC) to $106 from $108 and keeps a Buy rating on the shares. The firm is ...

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

DelveInsight's Dry Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of ...

Needham analysts adjusted their outlook on Alcon Inc. (NYSE: NYSE:ALC), reducing the price target to $106.00 from the previous $108.00, while still recommending a Buy rating for the stock. Currently ...

KeyBanc analyst Brett Fishbin revised the price target for Alcon Inc. (NYSE: NYSE:ALC) to $105.00, down from the previous target of $107.00, while continuing to endorse the stock with an Overweight ...

Clara Alcon, co-author of the study and researcher at the UB's Department of Biomedicine "Most cancer therapies that are used to fight cancer activate the process of apoptosis — a type of ...

DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence ...